BOC-甲基烯丙基甘氨酸 | 156047-41-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: BOC-甲基烯丙基甘氨酸
• 英文名称: 2-((tert-butoxycarbonyl)amino)-4-methylpent-4-enoic acid
• 英文别名: (2RS)-2-tert-Butoxycarbonylamino-4-methyl-4-pentenoic Acid；4-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pent-4-enoic Acid
• CAS: 156047-41-5
• 化学式: C₁₁H₁₉NO₄
• 分子量: 229.276
• InChiKey: YHWOMLAFEJVSSA-UHFFFAOYSA-N

物化性质

• 沸点：
  365.0±35.0 °C(Predicted)
• 密度：
  1.079±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  BOC-甲基烯丙基甘氨酸 在 N-甲基吗啉 、 lithium aluminium tetrahydride 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 2-甲基-2-丙基(4-甲基-1-氧代-4-戊烯-2-基)氨基甲酸酯
  参考文献：
  名称：

  Discovery of (1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a Selective, Potent, Orally Bioavailable Hepatitis C Virus NS3 Protease Inhibitor:  A Potential Therapeutic Agent for the Treatment of Hepatitis C Infection

  摘要：

  Hepatitis C virus (HCV) infection is the major cause of chronic liver disease, leading to cirrhosis and hepatocellular carcinoma, which affects more than 170 million people worldwide. Currently the only therapeutic regimens are subcutaneous interferon-alpha or polyethylene glycol (PEG)-interferon-alpha alone or in combination with oral ribavirin. Although combination therapy is reasonably successful with the majority of genotypes, its efficacy against the predominant genotype (genotype 1) is moderate at best, with only about 40% of the patients showing sustained virological response. Herein, the SAR leading to the discovery of 70 (SCH 503034), a novel, potent, selective, orally bioavailable NS3 protease inhibitor that has been advanced to clinical trials in human beings for the treatment of hepatitis C viral infections is described. X-ray structure of inhibitor 70 complexed with the NS3 protease and biological data are also discussed.

  DOI：

  10.1021/jm060325b
• 作为产物：
  描述：

  ethyl (2RS)-2-tert-butoxycarbonylamino-4-methyl-4-pentenoate 在 LiOH 作用下， 以 丙酮 为溶剂， 生成 BOC-甲基烯丙基甘氨酸
  参考文献：
  名称：

  Cysteinyl protease inhibitors

  摘要：

  具有C末端乙烯基的氨基酸二肽和三肽类似物，含有该类似物的药物组合物以及使用半胱氨酸蛋白酶抑制剂治疗疾病的方法；特别是神经退行性、自身免疫、认知障碍、中风和创伤性损伤。

  公开号：

  US06617426B1

文献信息

• [EN] MICROBIOCIDAL QUINOLINE DIHYDRO-(THIAZINE)OXAZINE DERIVATIVES<br/>[FR] DÉRIVÉS DE QUINOLÉINE DIHYDRO-(THIAZINE)OXAZINE MICROBIOCIDES
  申请人：SYNGENTA CROP PROTECTION AG

  公开号：WO2021204857A1

  公开（公告）日：2021-10-14

  Compounds of the formula (I): Formula (I) wherein the substituents are as defined in claim 1, useful as pesticides, especially as fungicides.

  式(I)的化合物：式(I)其中取代基如权利要求1中定义的那样，作为杀虫剂特别是作为杀菌剂有用。
• Cathepsin cysteine protease inhibitors
  申请人：——

  公开号：US20030232863A1

  公开（公告）日：2003-12-18

  This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

  这项发明涉及一类新型化合物，它们是半胱氨酸蛋白酶抑制剂，包括但不限于对卡特普辛K、L、S和B的抑制剂。这些化合物可用于治疗需要抑制骨吸收的疾病，如骨质疏松症。
• [EN] HIV PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE LA PROTÉASE DU VIH
  申请人：MERCK & CO INC

  公开号：WO2009042093A1

  公开（公告）日：2009-04-02

  Compounds of Formula I are disclosed: (I), wherein XA, k, R1, R2, R3, R4, R5, R5A, R6, R6A, R7 and R8 are defined herein. The compounds encompassed by Formula I include compounds which are HIV protease inhibitors and other compounds which can be metabolized in vivo to HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

  已披露的I式化合物：(I)，其中XA、k、R1、R2、R3、R4、R5、R5A、R6、R6A、R7和R8在此定义。公式I所包括的化合物包括HIV蛋白酶抑制剂和其他可在体内代谢为HIV蛋白酶抑制剂的化合物。这些化合物及其药用盐可用于预防或治疗HIV感染以及预防、治疗或延缓艾滋病的发作。这些化合物及其盐可用作药物组成部分，可选择性地与其他抗病毒药物、免疫调节剂、抗生素或疫苗组合使用。
• Cysteinyl protease inhibitors
  申请人：——

  公开号：US06617426B1

  公开（公告）日：2003-09-09

  Amino acid di- and tri-peptide analogs having C-terminal vinylic groups, pharmaceutical compositions containing the analogs and methods of treating diseases using cysteinyl protease inhibitors; particularly neurodegenerative, autoimmune, cognitive disorders, stroke and traumatic injury.

  具有C末端乙烯基的氨基酸二肽和三肽类似物，含有该类似物的药物组合物以及使用半胱氨酸蛋白酶抑制剂治疗疾病的方法；特别是神经退行性、自身免疫、认知障碍、中风和创伤性损伤。
• [EN] CATHEPSIN CYSTEINE PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE CATHEPSINE CYSTEINE PROTEASE
  申请人：MERCK FROSST CANADA INC

  公开号：WO2003075836A2

  公开（公告）日：2003-09-18

  This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

  本发明涉及一种新型化合物类别，它们是半胱氨酸蛋白酶抑制剂，包括但不限于对卡特普辛K、L、S和B的抑制剂。这些化合物可用于治疗需要抑制骨吸收的疾病，例如骨质疏松症。